PT  - JOURNAL ARTICLE
AU  - Hattori, Yosuke
AU  - Kojima, Toshihisa
AU  - Kaneko, Atsushi
AU  - Kida, Daihei
AU  - Hirano, Yuji
AU  - Fujibayashi, Takayoshi
AU  - Terabe, Kenya
AU  - Yabe, Yuichiro
AU  - Miyake, Hiroyuki
AU  - Kato, Takefumi
AU  - Takagi, Hideki
AU  - Hayashi, Masatoshi
AU  - Ito, Takayasu
AU  - Kanayama, Yasuhide
AU  - Oguchi, Takeshi
AU  - Takahashi, Nobunori
AU  - Ishikawa, Hisato
AU  - Funahashi, Koji
AU  - Ishiguro, Naoki
TI  - Longterm Retention Rate and Risk Factors for Adalimumab Discontinuation Due To Efficacy and Safety in Japanese Patients with Rheumatoid Arthritis: An Observational Cohort Study
AID  - 10.3899/jrheum.151006
DP  - 2016 Aug 01
TA  - The Journal of Rheumatology
PG  - 1475--1479
VI  - 43
IP  - 8
4099  - http://www.jrheum.org/content/43/8/1475.short
4100  - http://www.jrheum.org/content/43/8/1475.full
SO  - J Rheumatol2016 Aug 01; 43
AB  - Objective. To evaluate the rates of retention and discontinuation of adalimumab (ADA) due to efficacy and safety in Japanese patients with rheumatoid arthritis (RA).Methods. All patients with RA (n = 476) who were treated with ADA in the Tsurumai Biologics Communication Registry were enrolled.Results. The retention rate of ADA was 46% at 5 years. When focusing on insufficient efficacy, previous biologics use and high baseline disease activity were significant risk factors for up to 1 year. Methotrexate (MTX) use was a significantly low risk factor after 1 year of treatment.Conclusion. Concomitant MTX contributes to the longterm efficacy of ADA therapy.